Trial · NCT03360539
Registered outcomes60
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 60
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Number of Participants Who Received Adequate Prenatal Care | At index birth; vital records | With adequacy defined using the Adequacy of Prenatal Care Utilization Index (APNCU), where prenatal care began by the 4th month and at least 80% of recommended visits were attended |
| Secondary | Number of Emergency Department Visits During Pregnancy | At index birth; hospital discharge | Number of emergency department visits during pregnancy. |
| Secondary | Number of Participants With a Dental Visit During Pregnancy | At index birth; Medicaid claims and dental records | Number of participants with a dental visit during pregnancy (preventive or treatment). |
| Secondary | Number of Participants With an Ultrasound at 18-22 Weeks | 18-22 weeks gestation during index pregnancy. Assessed at index birth using Medicaid claims. | Number of participants with an ultrasound (anatomy scan) at 18-22 weeks. |
| Secondary | Number of Participants Who Received Prenatal Screens | At index birth; Medicaid claims | Our original prenatal screening outcome variable included the obstetric panel: Rhesus-D (DRh), red blood cell (RBC) antibody screen, complete blood count (CBC), urine culture, urinalysis; sexually transmitted infection (STI) screenings (HIV, syphilis, hepatitis B, chlamydia if \<25, gonorrhea if \<25); Group B strep screening, and glucose screening. However, since most participants had already completed their first prenatal visit prior to enrolling in the trial (when many of these tests are performed), it was not appropriate to include first-visit tests as outcomes. We therefore modified the outcome to instead use three clinically relevant measures that could occur after enrollment: glucose screening, Group B strep screening, and Tdap vaccination. These outcomes are reported as they appear in the published papers. |
| Secondary | Number of Participants Who Received a Gestational Diabetes Test (24-28 Weeks) | At 24-28 weeks' gestation of index pregnancy; Medicaid claims | Received a glucose screen at 24-28 weeks' gestation. Note: Our original prenatal screening outcome variable included the obstetric panel (D \[Rh\], RBC antibody screen, CBC, urine culture, urinalysis), STI screenings (HIV, syphilis, hepatitis B, chlamydia if \<25, gonorrhea if \<25), Group B strep screening, and glucose screening. However, since most participants had already completed their first prenatal visit prior to enrolling in the trial (when many of these tests are performed), it was not appropriate to include first-visit tests as outcomes. We therefore modified the outcome to instead use three clinically relevant measures that could occur after enrollment: glucose screening, Group B strep screening, and Tdap vaccination. These outcomes are reported as they appear in the published papers. |
| Secondary | Number of Participants With a Tdap Vaccination (27-36 Weeks) | At 27-36 weeks' gestation of index pregnancy; Medicaid claims | Received Tdap vaccination at 27-36 weeks' gestation. Our original prenatal screening outcome variable included the obstetric panel (D \[Rh\], RBC antibody screen, CBC, urine culture, urinalysis), STI screenings (HIV, syphilis, hepatitis B, chlamydia if \<25, gonorrhea if \<25), Group B strep screening, and glucose screening. However, since most participants had already completed their first prenatal visit prior to enrolling in the trial (when many of these tests are performed), it was not appropriate to include first-visit tests as outcomes. We therefore modified the outcome to instead use three clinically relevant measures that could occur after enrollment: glucose screening, Group B strep screening, and Tdap vaccination. These outcomes are reported as they appear in the published papers. |
| Secondary | Number of Participants With a Group B Streptococcus Test (35-37 Weeks) | At 35-37 weeks' gestation of index pregnancy; Medicaid claims | Received Group B streptococcus test at 35-37 weeks' gestation. Note: Our original prenatal screening outcome variable included the obstetric panel (D \[Rh\], RBC antibody screen, CBC, urine culture, urinalysis), STI screenings (HIV, syphilis, hepatitis B, chlamydia if \<25, gonorrhea if \<25), Group B strep screening, and glucose screening. However, since most participants had already completed their first prenatal visit prior to enrolling in the trial (when many of these tests are performed), it was not appropriate to include first-visit tests as outcomes. We therefore modified the outcome to instead use three clinically relevant measures that could occur after enrollment: glucose screening, Group B strep screening, and Tdap vaccination. These outcomes are reported as they appear in the published papers. |
| Secondary | Number of Participants With a Mental Health Diagnosis or Outpatient Treatment | During index pregnancy or 60 days postpartum; Medicaid claims | Diagnosis for depression/anxiety/stress reaction or antidepressant prescription or outpatient mental health visit |
| Secondary | Number of Participants With a Diagnosis of Depression/Anxiety/Stress Reaction | During index pregnancy or 60 days postpartum; Medicaid claims | Number of participants with a diagnosis of depression/anxiety/stress reaction. |
| Secondary | Number of Participants With an Antidepressant Prescription | During index pregnancy or 60 days postpartum; Medicaid claims | Number of participants with an antidepressant prescription. |
| Secondary | Number of Participants With an Outpatient Mental Health Visit | During index pregnancy or 60 days postpartum; Medicaid claims | Number of participants with at least one outpatient mental health visit. |
| Secondary | Number of Participants With a Mental Health Treatment Follow up | Within 120 days of treatment initiation; Medicaid claims | Second antidepressant prescription or outpatient mental health visit within 120 days of treatment initiation ("acute phase") |
| Secondary | Number of Participants With a Mental Health Related Emergency/Inpatient Visit | During index pregnancy or 12 months postpartum; Hospital discharge | Based on all-listed diagnoses (i.e. primary or secondary) for depression/anxiety/stress reaction |
| Secondary | Number of Mental Health Related Emergency/Inpatient Visits | During index pregnancy or 12 months postpartum; Hospital discharge | Based on all-listed diagnoses (i.e. primary or secondary) for depression/anxiety/stress reaction |
| Secondary | Number of Participants Whose Child Experienced a Major Injury | Within 24 months after index birth; Medicaid claims, hospital discharge, mortality records | Health care encounter or mortality associated with ICD codes indicating major injury |
| Secondary | Number of Participants Whose Child Experienced Concern for Abuse or Neglect | Within 24 months after index birth; Medicaid claims, hospital discharge, mortality records | Health care encounter or mortality associated with ICD codes indicating concern for abuse or neglect |
| Secondary | Number of Injuries | Within 24 months after index birth; hospital discharge | Number of injuries for child |
| Secondary | Number of Participants Whose Child Had an Emergency Department Visit | Within 24 months after index birth; hospital discharge | Number of participants whose child had at least one visit to the emergency department. |
| Secondary | Number of Child Emergency Department Visits | Within 24 months after index birth; hospital discharge | Total number of child visits to the emergency department (without admission) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03360539/registered?page=2